Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

Jim Miller

Outsourcing Outlook

http://www.pharmsource.com

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report, a monthly newsletter covering the contract drug development industry. A trial subscription can be obtained by calling 703.383.4903, by faxing 703.383.4905, by e-mailing info@pharmsource.com, or on the Web at www.pharmsource.com.

Articles
Contract Services Ride High As Funding Floods Biopharma
September 1, 2014

The contract services industry?s success is largely a result of the improved financial environment, rather than an increased acceptance of outsourcing.

When Payers Refuse to Cover New Drugs, CMOs Take a Hit
August 4, 2014

More health systems are saying ?no? to reimbursements for new drugs; CMOs must adjust strategies.

Positive Outlook for Outsourcing
August 1, 2014

Contract services ride high as funding floods bio/pharma.

Health Systems Raise the Bar on Reimbursing New Drugs
July 2, 2014

As payers refuse to cover new drugs, CMOs take a hit.

Are CMOs Out of Synch With Market Realities?
May 30, 2014

Why can't the CMO industry break through to manufacture a greater share of drugs?

Stuck in Neutral
May 2, 2014

The CMO industry's value proposition is limiting its market penetration.

How Will CMO Ownership Changes Impact Market?
April 1, 2014

Changes in company ownership shake up the CMO industry.

Under New Ownership
March 2, 2014

Changes in company ownership shake up the CMO industry.

Evolving R&D Model Pressures Contract Services Market
January 31, 2014

The R&D model is in transition and creating new demands on contract services providers.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here